Morgan Stanley raised the firm’s price target on Medacta Group (MEDGF) to CHF 146 from CHF 136 and keeps an Overweight rating on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MEDGF:
- Medacta Group SA Reports Strong 2024 Financial Growth
- Medacta Group SA Achieves Robust Growth in 2024 with Innovative Orthopedic Solutions
- Medacta Group SA: Strong Financial Performance and Growth Potential Justify Buy Rating
- Medacta Group price target raised to CHF 160 from CHF 150 at Berenberg
- Medacta Group price target raised to CHF 136 from CHF 135 at Morgan Stanley